Improving medication adherence in rheumatoid arthritis patients
Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis
This study is testing a new way to help people with rheumatoid arthritis stick to their medication plan by working closely with pharmacists and doctors to see if it works better than regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 2 sites (Pierre-Bénite, Lyon and 1 other locations) |
| Trial ID | NCT05413759 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance medication adherence among patients with rheumatoid arthritis (RA) through a collaborative intervention involving pharmacists and physicians. The intervention begins during hospitalization and continues after discharge, focusing on disease-modifying treatments. The effectiveness of this multiprofessional approach will be compared to standard care over a 12-month period, with adherence measured by the Medication Possession Ratio (MPR).
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and over with a diagnosed case of rheumatoid arthritis who are hospitalized or attending a rheumatology consultation.
Not a fit: Patients with significant cognitive or psychiatric disorders that would prevent them from participating effectively in the study may not benefit.
Why it matters
Potential benefit: If successful, this approach could significantly improve the health status and quality of life for patients with rheumatoid arthritis by ensuring better adherence to their medication regimen.
How similar studies have performed: Other studies have shown promising results with similar collaborative approaches to medication adherence, indicating potential for success in this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with diagnosed rheumatoid arthritis (RA), * Patient, male or female, aged 18 or over, * Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge * Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD), * Autonomous patient in the management of his drug treatment, * Patient understanding and speaking French, * Patient affiliated to the French general national health insurance or similar, * Patient having given his free, informed and signed consent. Exclusion Criteria: * Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study, * Patient whose regular pharmacy is currently treating another patient. * Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator), * Patient whose management of his drug treatment at home is carried out exclusively by a carer, * Patient participating in another research that may interfere (investigator's judgement) with the results of the present study, * Adult patient protected under the terms of the law (Public Health Code), * Patient not fit to carry out the follow-up, according to the judgment of the investigator, * Pregnant or breastfeeding women.
Where this trial is running
Pierre-Bénite, Lyon and 1 other locations
- Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon — Pierre-Bénite, Lyon, France (Not_yet_recruiting)
- Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot — Lyon, France (Recruiting)
Study contacts
- Principal investigator: Roland CHAPURLAT, MD/PHD — Hospices Civils de Lyon
- Study coordinator: Roland CHAPURLAT, MD/PHD
- Email: roland.charpulat@chu-lyon.fr
- Phone: 04 72 11 74 82
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.